Update on ongoing Dupixent (dupilumab) chronic spontaneous urticaria Phase 3 program In a Phase 3 trial in patients refractory to omalizumab, Dupixent did not reach statistical significance in
/PRNewswire/ In a Phase 3 trial in patients refractory to omalizumab, Dupixent did not reach statistical significance in interim analysis despite numeric.
/PRNewswire/ If approved, Dupixent will be the first biologic medicine available in the U.S. to treat uncontrolled moderate-to-severe atopic dermatitis for.